Clinical Analysis of Fuzheng Yiliu Decoction with Ultrasound Introduction as Adjuvant Treatment for Primary Liver Cancer

SUN Fang; ZHENG Qiu-hui; WANG Shu-ping; WANG Fa-lin

doi:10.13422/j.cnki.syfjx.2016010181

您当前的位置：

首页 >

文章列表页 >

Clinical Analysis of Fuzheng Yiliu Decoction with Ultrasound Introduction as Adjuvant Treatment for Primary Liver Cancer

更新时间：2024-01-04

- Clinical Analysis of Fuzheng Yiliu Decoction with Ultrasound Introduction as Adjuvant Treatment for Primary Liver Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 22, Issue 1, Pages: 181-185(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2016010181
  CLC： R735.7
- Published：2016
- 稿件说明：
移动端阅览
SUN Fang, ZHENG Qiu-hui, WANG Shu-ping, et al. Clinical Analysis of Fuzheng Yiliu Decoction with Ultrasound Introduction as Adjuvant Treatment for Primary Liver Cancer[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(1): 181-185.
DOI：

SUN Fang, ZHENG Qiu-hui, WANG Shu-ping, et al. Clinical Analysis of Fuzheng Yiliu Decoction with Ultrasound Introduction as Adjuvant Treatment for Primary Liver Cancer[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(1): 181-185. DOI： 10.13422/j.cnki.syfjx.2016010181.

摘要

目的: 探讨扶正抑瘤方超声导入辅助治疗原发性肝癌的疗效以及对血清高尔基体糖蛋白-73(GP-73)和磷脂酰肌醇蛋白聚糖3(GPC3)的影响。方法: 本研究共纳入120例原发性肝癌患者

根据治疗方法不同分为治疗组和对照组各60例;对照组进行肝动脉化疗栓塞术治疗;治疗组同对照组术后3 d给予扶正抑瘤方超声导入

1次/d

连续治疗12周;比较两组治疗前后主要症状、肝功能指标和T淋巴细胞亚群变化;检测两组血清GP-73和GPC3水平。结果: 治疗后治疗组临床总改善率为86.67%

对照组为58.33%

治疗组明显高于对照组(P<0.05);治疗组治疗后患者主要症状评分和肝功能指标丙氨酸氨基转移酶(ALT)

天门冬氨酸氨基转移酶(AST)

γ-谷氨酰转肽酶(γ-GT)和总胆红素(TBIL)均明显低于对照组(P<0.01);治疗组治疗后分化簇3(CD3+)

CD4+和CD4+/CD8+均高于对照组

而CD8+低于对照组(P<0.01);治疗后治疗组血清GP-73和GPC3水平明显低于对照组

比较差异有统计学意义(P<0.01)。结论: 扶正抑瘤方超声导入辅助治疗原发性肝癌能明显改善患者临床症状和生活质量

抑制血清GP-73和GPC3表达

从而改善免疫和肝功能。

Abstract

Objective: To discuss the clinical efficacy of Fuzheng Yiliu decoction with ultrasound introduction as an adjuvant treatment for primary liver cancer and its influence on serum golgi glycoprotein-73(GP-73) and glypican-3(GPC-3). Method: One hundred and twenty primary liver cancer patients were included in the study. According to different therapeutic methods

patients were randomly divided into the control group and treatment group

60 cases in each group. In the control group

patients were treated with hepatic arterial chemoembolization. Based on the treatment of the control group

patients in treatment group were treated with additional Fuzheng Yiliu decoction with ultrasound introduction(1 time/d) 3 days after surgery in control group

for 12 continuous weeks. Changes of main symptoms

liver function indexes and T lymphoid subgroups were compared before and after treatment. Levels of GP-73 and GPC3 in the serum of both groups were detected. Result: The total effective rate of the treatment group was 86.67%

significantly higher than 58.33% in the control group after treatment(P<0.05). Main symptoms and liver function indexes alanine aminotransferase(ALT)

aspartate amino transferase(AST)

γ-glutamine(γ-GT) and total bilirubin(TBIL) in the treatment group were significantly lower than those of the control group after treatment(P<0.01). The levels of CD3+

CD4+and CD4+/CD8+ in the treatment group were higher than those of the control group after treatment

while the level of CD8+ in the treatment group was lower than that in control group(P<0.01). After treatment

the levels of GP-73 and GPC3 in the serum of the treatment group were significantly lower than those in the control group

with statistical significance(P<0.01). Conclusion: Fuzheng Yiliu decoction with ultrasound introduction as an adjuvant treatment for primary liver cancer could evidently improve the clinical symptoms and quality of life

inhibit serum levels of GP-73 and GPC3

and improve immune and liver functions.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effects of Jianpi Bushen Prescription on Hematopoiesis and Immune System in Tumor Patients After Radiotherapy

Mechanism of Shenqi Yiliu Prescription Combined with Cisplatin on H22 Liver Cancer-bearing Mice Based on NLRP3/Caspase-1/GSDMD Pyroptosis Pathway

Effect of Modified Gualou Zhishitang Combined with Piperacillin Sodium and Tazobactam Sodium on Immune Function and Serum Levels of Inflammatory Cytokines in Patients with Stroke-associated Pneumonia with Syndrome of Phlegm-heat Accumulation in Lung

Clinical Effect of Fangfeng Tongshengsan on Post-chemoembolization Syndrome with Primary Liver Cancer or Postoperative Liver Metastases of Colorectal Cancer

Clinical Efficacy of Qimai Qinlou Prescription in Treating Elderly Community-acquired Pneumonia （Non-severe） with Qi and Yin Deficiency and Phlegm-heat Obstructing Lung Syndrome

Related Author

SUN Junyang

HE Dongchu

YANG Mengying

DUAN Yongqiang

JIA Yuxin

BAI Min

ZHU Zhongbo

LI Yarong

Related Institution

Central Theater General Hospital of PLA

Hubei University of Chinese Medicine

General Hospital of Ningxia Medical University

Gansu Province Experimental Animal Industry Technology Center

Key Laboratory of Study on Integrated Traditional Chinese and Western Medicine with High Incidence Diseases in Ningxia

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰